Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas

Veterinary Pathology

Volumn 46, Issue 4, 2009, Pages 736-745

  Radaelli, E ^a   Arnold, A ^b   Papanikolaou, A ^b   Garcia Fernandez, R A ^c   Mattiello, S ^a   Scanziani, E ^a   Cardiff, R D ^d  

^a Faculty of Veterinary Medicine   (Italy)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epithelial to mesenchymal transition; Estrogen receptor alpha; FVB N mice; Immunohistochemistry; Mammary carcinogenesis; Parity status; Prolactin

Indexed keywords

AGE; ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CASE REPORT; DISEASE MODEL; EXPERIMENTAL NEOPLASM; FEMALE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MOUSE; PATHOLOGY; PHENOTYPE; PREVALENCE; PROLACTINOMA; RISK FACTOR; TRANSGENIC MOUSE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; PHENOTYPE; PITUITARY NEOPLASMS; PREVALENCE; PROLACTINOMA; RISK FACTORS;

MUS;

EID: 67650889517     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1354/vp.08-VP-0280-R-FL     Document Type: Article

References (39)

1. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM: Estrogen receptor- positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261, 2005
2. Barthold SW: Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes. Genetica 122:75-88, 2004
3. Cardiff RD: Pathologists needed to cope with mutant mice. Nature 31:447-528, 2007
4. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19:968-988, 2000
5. Cardiff RD, Rosner A, Hogarth MA, Galvez JJ, Borowsky AD, Gregg JP: Validation: the new challenge for pathology. Toxicol Pathol 32:31-39, 2004
6. Chandra M, Frith CH: Spontaneous neoplasms in aged CD-1 mice. Toxicol Lett 61:67-74, 1992
7. Chandra M, Frith CH: Spontaneous neoplasms in B6C3F1 mice. Toxicol Lett 60:91-98, 1992
8. Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K: Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor- negative breast cancer cells. J Natl Cancer Inst 92:1403-1413, 2000
9. Christov KT, Guzman RC, Swanson SM, Thordar-son G, Talamantes F, Nandi S: Cell proliferation and apoptosis during mammary carcinogenesis in pituitary isografted mice. Carcinogenesis 8: 1741-1746, 1996
10. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC: Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 33:726-737, 2005
11. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD: EMT tumorigenesis in the mouse mammary gland. Lab Invest 87:1218-1226, 2007
12. Engelman RW, Day NK, Good RA: Calories, parity, and prolactin influence mammary epithelial kinetics and differentiation and alter mouse mammary tumor risk. Cancer Res 53:1188-1194, 1993
13. Felicio LS, Nelson JF, Finch CE: Spontaneous pituitary tumorigenesis and plasma oestradiol in ageing female C57BL/6J mice. Exp Gerontol 15:139-143, 1980
14. Gutzman JH, Miller KK, Schuler LA: Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 88:69-77, 2004
15. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA: Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol Endocrinol 19:1765-1778, 2005
16. Harvey PW: Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 25:179-183, 2005
17. Hoenerhoff MJ, Starost MF, Ward JM: Eosinophilic crystalline pneumonia as a major cause of death in 129S4/SvJae mice. Vet Pathol 43:682-688, 2006
18. Horwitz KB, McGuire WL: Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189:726-727, 1975
19. Huseby RA, Soares MJ, Talamantes F: Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology 116:1440-1448, 1985
20. Inano H, Suzuki K, Onoda M, Kobayashi H, Wakabayashi K: Radiation-induced tumorigenesis of mammary glands in pituitary transplanted rats ovariectomized before onset of estrous cycle. Cancer Lett 138:93-100, 1999
21. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185:191-203, 2007
22. Kumar R, Wang RA, Bagheri-Yarmand R: Emerging roles of MTA family members in human cancers. Semin Oncol 30:30-37, 2003
23. Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA: Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 66:1923-1928, 2006
24. Maglione JE, McGoldrick ET, Young LJ, Namba R, Gregg JP, Liu L, Moghanaki D, Ellies LG, Borowsky AD, Cardiff RD, MacLeod CL: Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther 3:941-953, 2004
25. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR: Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 24:710-716, 1996
26. Mikaelian I, Blades N, Churchill GA, Fancher K, Knowles BB, Eppig JT, Sundberg JP: Proteotypic classification of spontaneous and transgenic mammary neoplasms. Breast Cancer Res 6:668-679, 2004
27. Mishra SK, Talukder AH, Gururaj AE, Yang Z, Singh RR, Mahoney MG, Franći C, Vadlamudi RK, Kumar R: Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem 279:32709-32715, 2004
28. Miyoshi K, Shillingford JM, Le Provost F, Gounari F, Bronson R, von Boehmer H, Taketo MM, Cardiff RD, Hennighausen L, Khazaie K: Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 99:219-224, 2002
29. Nieto AI, Shyamala G, Galvez JJ, Thordarson G, Wakefield LM, Cardiff RD: Persistent mammary hyperplasia in FVB/N mice. Comp Med 53:433-438, 2003
30. Pedram A, Razandi M, Wallace DC, Levin ER: Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17:2125-2137, 2006
31. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA: Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22:4664-4674, 2003
32. Sarkar NH, Fernandes G, Telang NT, Kourides IA, Good RA: Low-calorie diet prevents the development of mammary tumors in C3H mice and reduces circulating prolactin level, murine mammary tumor virus expression, and proliferation of mammary alveolar cells. Proc Natl Acad Sci USA 79:7758-7762, 1982
33. SPSS: SPSS 15.0 for Windows, Vers. 15.0.1, SPSS Inc., Chicago, IL, 2006
34. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND: Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19:1077-1084, 2000
35. Wagner KU: Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res 6:31-38, 2004
36. Wakefield LM, Thordarson G, Nieto AI, Shyamala G, Galvez JJ, Anver MR, Cardiff RD: Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med 53:424-432, 2003
37. Welsch CW, Nagasawa H: Prolactin and murine mammary tumorigenesis: a review. Cancer Res 37:951-963, 1977
38. Willert K, Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20:1394-1404, 2006
39. Yang Z, Barnes CJ, Kumar R: Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10:3621-3628, 2004